Want to see JP:2395 full AI Analyst Report?
Shin Nippon Biomedical Laboratories, Ltd. (2395) AI Stock Analysis
Top Page
Shin Nippon Biomedical Laboratories, Ltd.
(TSE/TYO:2395)
The score is anchored by mixed financial performance (cooling revenue/margins, higher leverage, and inconsistent free cash flow) offset by strong technical positioning (price above key moving averages with positive MACD) and supportive valuation (low P/E and healthy dividend yield).
Shin Nippon Biomedical Laboratories, Ltd. (2395) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 62.70B
- Dividend Yield
- 3.32%
- Average Volume (3M)
- 240.66K
- Price to Earnings (P/E)
- 11.7
- Beta (1Y)
- 0.82
- Revenue Growth
- 1.72%
- EPS Growth
- 6.07%
- Country
- Japan
- Employees
- 1,680
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Shin Nippon Biomedical Laboratories, Ltd. Business Overview & Revenue Model
Company Description
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide array...
How the Company Makes Money
The company primarily makes money by providing fee-for-service contract research services to pharmaceutical, biotechnology, and other life science customers. Its core revenue model is based on customers paying for outsourced research work (typically...
Shin Nippon Biomedical Laboratories, Ltd. Financial Statement Overview
Summary
Profitable with healthy gross margin (~49%) and net margin (~14%), but fundamentals have softened: revenue declined (~2.5% in 2026), margins have compressed versus 2022–2023, leverage has risen (debt-to-equity near 1.0), and free cash flow has been volatile with weak cash conversion (OCF ~21% of net income in 2026).
Income Statement
68PositiveBalance Sheet
62PositiveCash Flow
44Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.92B | 32.52B | 32.41B | 26.45B | 25.09B | 17.75B |
| Gross Profit | 16.81B | 15.83B | 16.57B | 14.28B | 13.05B | 9.69B |
| EBITDA | 7.78B | 6.09B | 8.83B | 8.98B | 9.49B | 9.49B |
| Net Income | 5.37B | 4.57B | 4.92B | 5.53B | 6.06B | 7.13B |
Balance Sheet | ||||||
| Total Assets | 100.21B | 105.06B | 92.42B | 76.30B | 58.31B | 39.38B |
| Cash, Cash Equivalents and Short-Term Investments | 14.33B | 18.54B | 12.03B | 10.61B | 10.53B | 7.00B |
| Total Debt | 37.58B | 41.26B | 34.61B | 26.33B | 18.93B | 9.28B |
| Total Liabilities | 57.94B | 61.57B | 52.33B | 42.14B | 31.95B | 19.66B |
| Stockholders Equity | 41.73B | 43.12B | 40.02B | 34.11B | 26.21B | 19.56B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 3.15B | -3.82B | -6.50B | -951.70M | 4.34B |
| Operating Cash Flow | 0 | 8.33B | 7.04B | 2.11B | 4.00B | 5.95B |
| Investing Cash Flow | 0 | -6.79B | -11.69B | -6.91B | -5.93B | -4.27B |
| Financing Cash Flow | 0 | 4.51B | 5.91B | 5.32B | 6.27B | -4.91B |
Shin Nippon Biomedical Laboratories, Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2395, the sentiment is Positive. The current price of 1506.00 is above the 20-day moving average (MA) of 1446.25, above the 50-day MA of 1384.60, and above the 200-day MA of 1378.99, indicating a bullish trend. The MACD of 40.55 indicates Negative momentum. The RSI at 61.92 is Neutral, neither overbought nor oversold. The STOCH value of 84.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2395.
Shin Nippon Biomedical Laboratories, Ltd. Peers Comparison
Overall Rating
JP:469472Outperform- JP:239566Neutral
JP:454957Neutral
JP:218350Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4694 | 72Outperform | JPY 143.41B | 18.36 | 6.22% | 3.32% | 3.88% | 26.78% |
| JP:2395 | 66Neutral | JPY 62.70B | 11.67 | ― | 3.32% | 1.72% | 6.07% |
| JP:4549 | 57Neutral | JPY 76.06B | 41.05 | ― | 2.51% | 3.92% | -52.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:2183 | 50Neutral | JPY 4.52B | -1.19 | ― | 4.00% | -21.55% | -497.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2395 | Shin Nippon Biomedical Laboratories, Ltd. | 1506.00 | 99.20 | 7.05% | |
| JP:4694 | BML | 3835.00 | 297.80 | 8.42% | |
| JP:2183 | Linical Co., Ltd. | 200.00 | -131.75 | -39.71% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2307.00 | 3.99 | 0.17% |
Shin Nippon Biomedical Laboratories, Ltd. Corporate Events
SNBL Corrects Earnings Per Share Figure in Q1 FY2026 Disclosure
Shin Nippon Biomedical Laboratories has corrected an error in its consolidated financial results release for the three months ended June 30, 2026, specifically in the summary information on page one. The revision concerns the basic earnings per share...
Shin Nippon Biomedical Laboratories Lifts First-Half Earnings Forecast on Strong CRO Performance
Shin Nippon Biomedical Laboratories has sharply raised its consolidated earnings forecast for the first half of the fiscal year ending March 31, 2027, citing stronger-than-expected results in its CRO business. Revenue is now projected at ¥17,154...
SNBL Sets New Management Structure and Highlights FY3/27 Q1 CRO Strategy
Shin Nippon Biomedical Laboratories, Ltd. outlined its new management structure and future strategic direction alongside reporting an overview of first quarter results for the fiscal year ending March 31, 2027. The briefing highlighted consolidated f...
SNBL Delivers Strong Q1 Earnings and Confirms Dividend Outlook
Shin Nippon Biomedical Laboratories reported strong results for the quarter ended June 30, 2026, with revenue rising 21.5% year on year to ¥7,868 million and profit attributable to owners of the parent surging to ¥1,064 million. The turnaro...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 07, 2026